Ghaydaa Aldabie, Ahlam Almarzooqi, Shamma Al Nokhatha, Wesam Gouda, Mohammad Khudadah, Rawan Saleh, Maher Banjari, Roaa Aljohani, Samar Al-Emadi, Ali Jawad
{"title":"Pregnancy and reproductive care in Behçet's disease: clinical excellence across the maternal journey.","authors":"Ghaydaa Aldabie, Ahlam Almarzooqi, Shamma Al Nokhatha, Wesam Gouda, Mohammad Khudadah, Rawan Saleh, Maher Banjari, Roaa Aljohani, Samar Al-Emadi, Ali Jawad","doi":"10.1080/1744666X.2026.2669542","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Behçet's disease (BD) is a rare, multisystem inflammatory disorder predominantly affecting women during their reproductive years. Its potential impact on pregnancy outcomes makes understanding optimal management strategies crucial. Given the complexity and variability of this disease during pregnancy, there is a compelling need to review current evidence to guide clinical practice and improve maternal and neonatal outcomes.</p><p><strong>Areas covered: </strong>This narrative review consolidates recent literature from database inception to June 2025, focusing on disease course, reproductive implications, and obstetric outcomes in women with BD. It evaluates the safety of immunosuppressive therapies during conception, pregnancy, and lactation. The review highlights key aspects such as preconception planning, disease monitoring, delivery considerations, and postpartum care, drawing from a broad spectrum of clinical research, guidelines, and expert opinions.</p><p><strong>Expert opinion: </strong>The current evidence suggests that with personalized, multidisciplinary care and careful medication management, many women with BD can experience successful pregnancies. While existing data support the safety of several therapies and highlight the importance of preconception counseling, significant gaps remain due to limited high-quality prospective studies. Advancements in understanding disease mechanisms, developing standardized protocols, and establishing evidence-based guidelines are necessary to optimize care and further improve reproductive outcomes in this patient population.</p>","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1-11"},"PeriodicalIF":3.7000,"publicationDate":"2026-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Clinical Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1744666X.2026.2669542","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Behçet's disease (BD) is a rare, multisystem inflammatory disorder predominantly affecting women during their reproductive years. Its potential impact on pregnancy outcomes makes understanding optimal management strategies crucial. Given the complexity and variability of this disease during pregnancy, there is a compelling need to review current evidence to guide clinical practice and improve maternal and neonatal outcomes.
Areas covered: This narrative review consolidates recent literature from database inception to June 2025, focusing on disease course, reproductive implications, and obstetric outcomes in women with BD. It evaluates the safety of immunosuppressive therapies during conception, pregnancy, and lactation. The review highlights key aspects such as preconception planning, disease monitoring, delivery considerations, and postpartum care, drawing from a broad spectrum of clinical research, guidelines, and expert opinions.
Expert opinion: The current evidence suggests that with personalized, multidisciplinary care and careful medication management, many women with BD can experience successful pregnancies. While existing data support the safety of several therapies and highlight the importance of preconception counseling, significant gaps remain due to limited high-quality prospective studies. Advancements in understanding disease mechanisms, developing standardized protocols, and establishing evidence-based guidelines are necessary to optimize care and further improve reproductive outcomes in this patient population.
期刊介绍:
Expert Review of Clinical Immunology (ISSN 1744-666X) provides expert analysis and commentary regarding the performance of new therapeutic and diagnostic modalities in clinical immunology. Members of the International Editorial Advisory Panel of Expert Review of Clinical Immunology are the forefront of their area of expertise. This panel works with our dedicated editorial team to identify the most important and topical review themes and the corresponding expert(s) most appropriate to provide commentary and analysis. All articles are subject to rigorous peer-review, and the finished reviews provide an essential contribution to decision-making in clinical immunology.
Articles focus on the following key areas:
• Therapeutic overviews of specific immunologic disorders highlighting optimal therapy and prospects for new medicines
• Performance and benefits of newly approved therapeutic agents
• New diagnostic approaches
• Screening and patient stratification
• Pharmacoeconomic studies
• New therapeutic indications for existing therapies
• Adverse effects, occurrence and reduction
• Prospects for medicines in late-stage trials approaching regulatory approval
• Novel treatment strategies
• Epidemiological studies
• Commentary and comparison of treatment guidelines
Topics include infection and immunity, inflammation, host defense mechanisms, congenital and acquired immunodeficiencies, anaphylaxis and allergy, systemic immune diseases, organ-specific inflammatory diseases, transplantation immunology, endocrinology and diabetes, cancer immunology, neuroimmunology and hematological diseases.